News J&J hits back over asbestos in talc claims Shares in Johnson & Johnson slid around 10% on Friday after a Reuters article claimed the company had known for decades about asbestos in talcum powder products.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.